News
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
4d
Pharmaceutical Technology on MSNBeOne Medicines’ BTK degrader gains EMA PRIME designationThe designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...
8d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injectionThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results